Pórszász, RóbertMazor, ‪Nir2023-05-032023-05-032023-02-07https://hdl.handle.net/2437/351566Obesity is a chronic, progressive, relapsing, and curable multi-factorial neurobehavioral disorder in which an increase in body fat promotes adipose tissue malfunction and abnormal fat mass quantity and quality, leading to unfavorable metabolic, biomechanical, and psychosocial health consequences. The complexity of the problem is reflected in the complexity of the definition. Everyone accepts the more straightforward and pragmatic definition of overweight and obesity as a body mass index (BMI) of over 25 and 30, respectively. Obesity is a fast-rising public health problem worldwide. A deeper comprehension of the pathophysiology of obesity is necessary for the development of more effective treatments. Efforts to manage obesity obtain better outcomes of the disease, and aid in the future understanding of the pharmacological mechanism. Approved therapeutics are on the rise over the last few years for new anti-obesity medicines, with increasing evidence of the novel mono- and multi-agonist GLP1 GIP and Glucagon therapies that can affect tremendously weight loss and treatment of obesity. Warranting more studies, their approval and use in clinical practice will increase dramatically and might even close the gap between the efficacy seen with bariatric surgery and pharmacology.40enobesity managementobesityglp1 analogdual agonisttriple agonistDEENK Témalista::Orvostudomány::FarmakológiaDEENK Témalista::Orvostudomány::BelgyógyászatDEENK Témalista::Orvostudomány::CsaládorvoslásHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.